BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 17600289)

  • 1. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Ann N Y Acad Sci; 2007 Sep; 1112():357-67. PubMed ID: 17600289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of triple therapy with thymalfasin, peginterferon alpha-2a, and ribavirin for the treatment of hispanic chronic HCV nonresponders.
    Poo JL; Sánchez Avila F; Kershenobich D; García Samper X; Torress-Ibarra R; Góngora J; Cano C; Parada M; Uribe M
    Ann Hepatol; 2008; 7(4):369-75. PubMed ID: 19034238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
    Camerini R; Ciancio A; DE Rosa A; Rizzetto M
    Ann N Y Acad Sci; 2007 Sep; 1112():368-74. PubMed ID: 17600286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S79-81. PubMed ID: 15546256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymalfasin for the treatment of chronic hepatitis C infection.
    Rustgi VK
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):885-92. PubMed ID: 16307501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
    García-Contreras F; Nevárez-Sida A; Constantino-Casas P; Abud-Bastida F; Garduño-Espinosa J
    Arch Med Res; 2006 Jul; 37(5):663-73. PubMed ID: 16740439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymalfasin in the treatment of hepatitis B and C.
    Ciancio A; Rizzetto M
    Ann N Y Acad Sci; 2010 Apr; 1194():141-6. PubMed ID: 20536462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination of thymalfasin, peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior interferon and ribavirin treatment: 24-week interim results of a pilot study.
    Poo JL; Sánchez-Avila F; Kershenobich D; García-Samper X; Gongora J; Uribe M
    J Gastroenterol Hepatol; 2004 Dec; 19(12):S79-81. PubMed ID: 15641210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J
    N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
    Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
    N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.
    Andreone P; Gramenzi A; Cursaro C; Felline F; Loggi E; D'Errico A; Spinosa M; Lorenzini S; Biselli M; Bernardi M
    J Viral Hepat; 2004 Jan; 11(1):69-73. PubMed ID: 14738560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymosin alpha 1 in combination with interferon alpha and ribavirin in chronic hepatitis C patients who are non-responders or relapsers to interferon alpha plus ribavirin.
    Abbas Z; Hamid SS; Tabassum S; Jafri W
    J Pak Med Assoc; 2004 Nov; 54(11):571-4. PubMed ID: 15623184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C.
    Di Bisceglie AM; Ghalib RH; Hamzeh FM; Rustgi VK
    J Viral Hepat; 2007 Oct; 14(10):721-9. PubMed ID: 17875007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment.
    Rustgi V
    J Gastroenterol Hepatol; 2004 Dec; 19 Suppl 6():S76-8. PubMed ID: 15546255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
    J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
    Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
    JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of pegylated-interferon-alpha2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin.
    Ciancio A; Picciotto A; Giordanino C; Smedile A; Tabone M; Manca A; Marenco G; Garbagnoli P; Andreoni M; Cariti G; Calleri G; Sartori M; Cusumano S; Grasso A; Rizzi R; Gallo M; Basso M; Anselmo M; Percario G; Ciccone G; Rizzetto M; Saracco G
    Aliment Pharmacol Ther; 2006 Oct; 24(7):1079-86. PubMed ID: 16984502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.